Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Review article: panitumumab--a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer Peeters M; Balfour J; Arnold DAliment Pharmacol Ther 2008[Aug]; 28 (3): 269-81BACKGROUND: Panitumumab is a fully human monoclonal IgG2 antibody targeting the epidermal growth factor receptor (EGFR). AIM: To review the efficacy of panitumumab in the treatment of metastatic colorectal cancer (mCRC). METHODS: Available literature identified from PubMed and conference websites was reviewed. RESULTS: In phase 2-3 studies, panitumumab monotherapy achieved objective response rates (ORRs) of 8-13% in relapsed/refractory EGFR-expressing mCRC. In a randomized phase 3 study (463 patients), panitumumab almost halved the risk of disease progression/death vs. a control group receiving only best supportive care (hazard ratio 0.54; 95% CI: 0.44-0.66; P < 0.0001). Objective response was achieved in 22/231 (10%) patients randomized to panitumumab--and also in 20/176 (11%) patients assigned to the control group who received panitumumab in a separate crossover protocol after disease progression. Response was confined to patients with tumours harbouring wild-type KRAS (ORR approximately equal to 20%). Panitumumab is also being evaluated in earlier lines of treatment. Panitumumab monotherapy is generally well tolerated; the most common toxicities are skin toxicity (approximately equal to 90%) and diarrhoea (<30%). Development of anti-panitumumab antibodies (0.3% by ELISA) and grade 3-4 infusion reactions (<1%) are rare. CONCLUSION: Panitumumab is an effective monotherapy option for patients with relapsed/refractory EGFR-expressing mCRC harbouring wild-type KRAS.|Adenocarcinoma/*drug therapy/genetics/secondary[MESH]|Antibodies, Monoclonal, Humanized[MESH]|Antibodies, Monoclonal/administration & dosage[MESH]|Antineoplastic Combined Chemotherapy Protocols/*therapeutic use[MESH]|Biomarkers, Tumor/genetics[MESH]|Cetuximab[MESH]|Clinical Trials as Topic[MESH]|Colorectal Neoplasms/*drug therapy/genetics/secondary[MESH]|Disease-Free Survival[MESH]|Female[MESH]|Humans[MESH]|Immunoglobulin G/genetics[MESH]|Male[MESH]|Panitumumab[MESH]|Patient Selection[MESH]|Proto-Oncogene Proteins p21(ras)[MESH]|Proto-Oncogene Proteins/administration & dosage[MESH]|ras Proteins/administration & dosage[MESH] |